Creative Planning Astrazeneca PLC Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Astrazeneca PLC stock. As of the latest transaction made, Creative Planning holds 224,751 shares of AZN stock, worth $15.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

224,751

Previous 208,059 8.02%

Holding current value

$15.1 Million

Previous $16.2 Million 7.93%

% of portfolio

0.02%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	BUY	$76.67 - $87.62 $1.28 Million - $1.46 Million	16,692 Added 8.02%	224,751 $17.5 Million
Q2 2024 Aug 15, 2024	BUY	$66.81 - $80.83 $2.15 Million - $2.6 Million	32,132 Added 18.26%	208,059 $16.2 Million
Q1 2024 May 10, 2024	BUY	$61.03 - $69.57 $1.77 Million - $2.02 Million	29,057 Added 19.78%	175,927 $11.9 Million
Q4 2023 Feb 14, 2024	SELL	$61.89 - $69.28 $1.35 Million - $1.51 Million	-21,795 Reduced 12.92%	146,870 $9.89 Million
Q3 2023 Nov 16, 2023	BUY	$64.85 - $71.7 $855,306 - $945,651	13,189 Added 8.48%	168,665 $11.4 Million
Q2 2023 Jul 21, 2023	BUY	$69.91 - $75.81 $1.41 Million - $1.53 Million	20,172 Added 14.91%	155,476 $11.1 Million
Q1 2023 May 15, 2023	BUY	$63.15 - $71.6 $272,871 - $309,383	4,321 Added 3.3%	135,304 $9.39 Million
Q4 2022 Feb 10, 2023	BUY	$54.21 - $70.44 $953,770 - $1.24 Million	17,594 Added 15.52%	130,983 $8.88 Million
Q3 2022 Nov 03, 2022	BUY	$53.02 - $135.75 $651,668 - $1.67 Million	12,291 Added 12.16%	113,389 $6.22 Million
Q2 2022 Aug 15, 2022	BUY	$59.26 - $71.14 $26,726 - $32,084	451 Added 0.45%	101,098 $6.68 Million
Q1 2022 May 16, 2022	BUY	$55.72 - $67.12 $1.88 Million - $2.27 Million	33,809 Added 50.58%	100,647 $6.68 Million
Q4 2021 Feb 11, 2022	SELL	$54.02 - $63.83 $80,489 - $95,106	-1,490 Reduced 2.18%	66,838 $3.89 Million
Q3 2021 Nov 10, 2021	BUY	$55.56 - $60.79 $643,829 - $704,434	11,588 Added 20.42%	68,328 $4.1 Million
Q2 2021 Aug 04, 2021	SELL	$48.42 - $60.18 $452,339 - $562,201	-9,342 Reduced 14.14%	56,740 $3.4 Million
Q1 2021 Apr 30, 2021	SELL	$47.16 - $54.44 $83,991 - $96,957	-1,781 Reduced 2.62%	66,082 $3.29 Million
Q4 2020 Jan 29, 2021	BUY	$48.52 - $58.02 $144,686 - $173,015	2,982 Added 4.6%	67,863 $3.39 Million
Q3 2020 Nov 05, 2020	BUY	$53.07 - $61.1 $259,087 - $298,290	4,882 Added 8.14%	64,881 $3.56 Million
Q2 2020 Jul 23, 2020	BUY	$43.1 - $55.31 $461,644 - $592,425	10,711 Added 21.73%	59,999 $3.17 Million
Q1 2020 May 05, 2020	BUY	$37.79 - $51.33 $160,607 - $218,152	4,250 Added 9.44%	49,288 $2.2 Million
Q4 2019 Jan 30, 2020	BUY	$42.46 - $50.46 $156,677 - $186,197	3,690 Added 8.92%	45,038 $2.25 Million
Q3 2019 Nov 01, 2019	SELL	$40.12 - $45.47 $56,448 - $63,976	-1,407 Reduced 3.29%	41,348 $1.84 Million
Q2 2019 Jul 26, 2019	BUY	$37.28 - $41.68 $2,945 - $3,292	79 Added 0.19%	42,755 $1.77 Million
Q1 2019 Apr 24, 2019	SELL	$35.49 - $43.02 $105,156 - $127,468	-2,963 Reduced 6.49%	42,676 $1.73 Million
Q4 2018 Feb 01, 2019	BUY	$36.86 - $41.49 $160,599 - $180,771	4,357 Added 10.55%	45,639 $1.73 Million
Q3 2018 Oct 25, 2018	BUY	$34.76 - $39.72 $179,292 - $204,875	5,158 Added 14.28%	41,282 $1.63 Million
Q2 2018 Jul 20, 2018	SELL	$34.55 - $37.05 $16,100 - $17,265	-466 Reduced 1.27%	36,124 $1.27 Million
Q1 2018 Apr 18, 2018	BUY	$32.97 - $36.63 $5,802 - $6,446	176 Added 0.48%	36,590 $1.28 Million
Q4 2017 Jan 17, 2018	SELL	$32.09 - $34.78 $4,749 - $5,147	-148 Reduced 0.4%	36,414 $1.26 Million
Q3 2017 Oct 17, 2017	BUY	$28.96 - $34.0 $1.06 Million - $1.24 Million	36,562	36,562 $1.24 Million

Others Institutions Holding AZN

# of Institutions

1,361

Shares Held

475M

Call Options Held

5.39M

Put Options Held

3.75M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $208B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Astrazeneca PLC Transaction History